Eli Lilly Launches Multi-Dose Zepbound Pen to Drive Obesity Drug Growth
Eli Lilly unveiled a new multi-dose version of its blockbuster obesity drug Zepbound, allowing patients to receive a full month of doses in a single injection.
More Videos
Inside Nvidia’s Record Quarter and the Global AI Arms Race
Ray Wang of Constellation Research breaks down Nvidia’s blockbuster earnings and the future of the AI chip race.
How Xometry Is Transforming the Future of Manufacturing
Randy Altschuler, CEO of Xometry, discusses AI, automation and the rise of on-demand manufacturing.
The Billion-Dollar AI Breakup: Inside Musk’s Failed War Against OpenAI
Andrew Nusca, Editorial Director at Fortune, breaks down how Musk’s failed $150 billion lawsuit could reshape AI governance.
SpaceX, OpenAI and Anthropic Set the Stage for an IPO Frenzy
Jim Neesen of Connor Group discusses the AI-driven IPO boom, SpaceX, OpenAI, Anthropic and whether Wall Street can sustain the hype.
Why the Beijing Summit Could Reshape the Future of AI
Politico’s Aaron Mak breaks down the Trump-Xi Beijing summit, AI competition, semiconductor tensions and what it means for global tech.
Inside the Clarity Act: Can Washington Finally Bring Order to Crypto?
The Clarity Act could reshape U.S. crypto regulation by defining digital assets and resolving SEC–CFTC jurisdiction. Paul Grewal of Coinbase weighs in.
